Long-term use of ozanimod in patients with moderately to severely active ulcerative colitis

被引：0
|
作者：
Danese, S. [1 ]
Colombel, J-F [2 ]
Ponich, T. [9 ]
Jovanovic, I. [10 ]
Bossuyt, P. [11 ]
Longman, R. [3 ]
Alekseeva, O. [12 ]
Petersen, A. K. [4 ]
Marta, C. [4 ]
Charles, L. [4 ]
Sparrow, M. [13 ]
Rubin, D. T. [5 ]
Afzali, A. [6 ]
Loftus, E. V., Jr. [7 ]
Wolf, D. C. [8 ]
机构：
[1] IRCCS San Raffaele Hosp, Milan, Italy
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Weill Cornell Med, Jill Roberts Ctr Inflammatory Bowel Dis, New York, NY USA
[4] Bristol Myers Squibb, Princeton, NJ USA
[5] Univ Chicago, Med Inflammatory Bowel Dis Ctr, Chicago, IL USA
[6] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA
[7] Mayo Clin, Div Gastroenterol & Hepatol, Coll Med, Rochester, MN USA
[8] Atlanta Gastroenterol Assoc, Ctr Crohns Dis & Ulcerat Colitis, Atlanta, GA USA
[9] Western Univ, London, ON, Canada
[10] Univ Hosp Med Ctr Bezanijska Kosa, Div Gastroenterol, Belgrade, Serbia
[11] Imelda Gen Hosp, Imelda GI Clin Res Ctr, Bonheiden, Belgium
[12] Nizhny Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia
[13] Monash Univ, Alfred Hosp, Melbourne, Vic, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2022年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
89
引用
下载
收藏
页码：125 / 126
页数：2
相关论文
共 50 条
  • [1] Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis
    Danese, S.
    Colombel, J. F.
    Ponich, T.
    Jovanovic, I.
    Bossuyt, P.
    Longman, R.
    Alekseeva, O.
    Petersen, A.
    Chitkara, D.
    Marta, C.
    Charles, L.
    Rubin, D. T.
    Afzali, A.
    Loftus, E. V.
    Wolf, D. C.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I093 - I094
  • [2] LONG-TERM USE OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Wolf, Douglas C.
    Colombel, Jean Frederic
    Ponich, Terry P.
    Jovanovic, Igor
    Bossuyt, Peter
    Longman, Randy
    Alekseeva, Olga
    Petersen, AnnKatrin
    Chitkara, Denesh
    Marta, Cecilia
    Charles, Lorna
    Rubin, David T.
    Afzali, Anita
    Loftus, Edward V.
    Danese, Silvio
    GASTROENTEROLOGY, 2022, 162 (07) : S969 - S969
  • [3] Long-term Safety of Ozanimod in Relapsing Multiple Sclerosis and Moderately to Severely Active Ulcerative Colitis
    Cree, Bruce A. C.
    Danese, Silvio
    Wolf, Douglas C.
    Alekseeva, Olga
    Charles, Lorna
    Petersen, AnnKatrin
    Sheffield, James K.
    Cheng, Chun-Yen
    Riolo, Jon V.
    Silva, Diego
    Lublin, Fred D.
    Rubin, David T.
    Cohen, Jeffrey A.
    NEUROLOGY, 2023, 100 (17)
  • [4] Long-Term Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
    Rubin, David T.
    Cree, Bruce A. C.
    Wolf, Douglas C.
    Alekseeva, Olga
    Charles, Lorna
    Petersen, AnnKatrin
    Sheffield, James K.
    Cheng, Chun-Yen
    Riolo, Jon V.
    Silva, Diego
    Lublin, Fred D.
    Cohen, Jeffrey A.
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S680 - S680
  • [5] Long-term Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis (UC) and Relapsing Multiple Sclerosis (RMS) Studies
    Rubin, David T.
    Wolf, Douglas C.
    Alekseeva, Olga
    Charles, Lorna
    Afsari, Sonia
    Petersen, Ann Katrin
    Sheffield, James
    Li, Hongjuan
    Silva, Diego
    Lublin, Fred D.
    Cree, Bruce
    Cohen, Jeffrey
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S396 - S396
  • [6] Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis
    Colombel, Jean-Frederic
    Sandborn, William
    Wolf, Doug
    Panaccione, Remo
    Lazar, Andreas
    Kron, Martina
    Robinson, Anne
    Thakkar, Roopal
    INFLAMMATORY BOWEL DISEASES, 2012, 18 : S20 - S21
  • [7] Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis
    Colombel, Jean-Frederic
    Sandborn, William
    Wolf, Douglas
    Panaccione, Remo
    Lazar, Andreas
    Kron, Martina
    Robinson, Anne
    Thakkar, Roopal
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S652 - S652
  • [8] COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Dubinsky, Marla C.
    Betts, Keith
    Eren, Devrim
    Tang, Wenxi
    Yin, Lei
    Gupte-Singh, Komal
    GASTROENTEROLOGY, 2022, 162 (07) : S603 - S603
  • [9] A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis
    Aoun, Roni
    Hanauer, Stephen
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (05) : 411 - 423
  • [10] Predictors of time to relapse upon ozanimod withdrawal in patients with moderately to severely active ulcerative colitis
    Vermeire, S.
    Abraham, B.
    Bressler, B.
    Reinisch, W.
    Axelrad, J. E.
    Jain, A.
    Memaj, A.
    Akukwe, L.
    Liu, W. J.
    Osterman, M. T.
    Canavan, J. B.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 882 - 884
12345